The drug, made by fractionating the plasma of people who were recovering from Covid-19 or who had it asymptomatically, contains anti-SARS-CoV-2 immunoglobulins that can fight and neutralise the deadly virus.
Biomed Lublin has started production of the first batch of a drug for COVID-19 from convalescent plasma. It will be subjected to clinical trials that will begin in about two months, said representatives of Biomed and the Medical University of Lublin on Tuesday.
This site uses "cookies". By staying on it, you agree to the use of cookies.
